Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

463 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.
Zost SJ, Gilchuk P, Chen RE, Case JB, Reidy JX, Trivette A, Nargi RS, Sutton RE, Suryadevara N, Chen EC, Binshtein E, Shrihari S, Ostrowski M, Chu HY, Didier JE, MacRenaris KW, Jones T, Day S, Myers L, Lee FE, Nguyen DC, Sanz I, Martinez DR, Baric RS, Thackray LB, Diamond MS, Carnahan RH, Crowe JE. Zost SJ, et al. Among authors: chu hy. bioRxiv [Preprint]. 2020 May 13:2020.05.12.091462. doi: 10.1101/2020.05.12.091462. bioRxiv. 2020. Update in: Nat Med. 2020 Sep;26(9):1422-1427. doi: 10.1038/s41591-020-0998-x PMID: 32511414 Free PMC article. Updated. Preprint.
Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual.
Seydoux E, Homad LJ, MacCamy AJ, Parks KR, Hurlburt NK, Jennewein MF, Akins NR, Stuart AB, Wan YH, Feng J, Nelson RE, Singh S, Cohen KW, McElrath MJ, Englund JA, Chu HY, Pancera M, McGuire AT, Stamatatos L. Seydoux E, et al. Among authors: chu hy. bioRxiv [Preprint]. 2020 May 12:2020.05.12.091298. doi: 10.1101/2020.05.12.091298. bioRxiv. 2020. Update in: Immunity. 2020 Jul 14;53(1):98-105.e5. doi: 10.1016/j.immuni.2020.06.001 PMID: 32511342 Free PMC article. Updated. Preprint.
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.
Zost SJ, Gilchuk P, Chen RE, Case JB, Reidy JX, Trivette A, Nargi RS, Sutton RE, Suryadevara N, Chen EC, Binshtein E, Shrihari S, Ostrowski M, Chu HY, Didier JE, MacRenaris KW, Jones T, Day S, Myers L, Eun-Hyung Lee F, Nguyen DC, Sanz I, Martinez DR, Rothlauf PW, Bloyet LM, Whelan SPJ, Baric RS, Thackray LB, Diamond MS, Carnahan RH, Crowe JE Jr. Zost SJ, et al. Among authors: chu hy. Nat Med. 2020 Sep;26(9):1422-1427. doi: 10.1038/s41591-020-0998-x. Epub 2020 Jul 10. Nat Med. 2020. PMID: 32651581 Free PMC article.
Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2.
Walls AC, Fiala B, Schäfer A, Wrenn S, Pham MN, Murphy M, Tse LV, Shehata L, O'Connor MA, Chen C, Navarro MJ, Miranda MC, Pettie D, Ravichandran R, Kraft JC, Ogohara C, Palser A, Chalk S, Lee EC, Kepl E, Chow CM, Sydeman C, Hodge EA, Brown B, Fuller JT, Dinnon KH 3rd, Gralinski LE, Leist SR, Gully KL, Lewis TB, Guttman M, Chu HY, Lee KK, Fuller DH, Baric RS, Kellam P, Carter L, Pepper M, Sheahan TP, Veesler D, King NP. Walls AC, et al. Among authors: chu hy. bioRxiv [Preprint]. 2020 Aug 12:2020.08.11.247395. doi: 10.1101/2020.08.11.247395. bioRxiv. 2020. Update in: Cell. 2020 Nov 25;183(5):1367-1382.e17. doi: 10.1016/j.cell.2020.10.043 PMID: 32817941 Free PMC article. Updated. Preprint.
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
Cameroni E, Saliba C, Bowen JE, Rosen LE, Culap K, Pinto D, VanBlargan LA, De Marco A, Zepeda SK, Iulio JD, Zatta F, Kaiser H, Noack J, Farhat N, Czudnochowski N, Havenar-Daughton C, Sprouse KR, Dillen JR, Powell AE, Chen A, Maher C, Yin L, Sun D, Soriaga L, Bassi J, Silacci-Fregni C, Gustafsson C, Franko NM, Logue J, Iqbal NT, Mazzitelli I, Geffner J, Grifantini R, Chu H, Gori A, Riva A, Giannini O, Ceschi A, Ferrari P, Cippà P, Franzetti-Pellanda A, Garzoni C, Halfmann PJ, Kawaoka Y, Hebner C, Purcell LA, Piccoli L, Pizzuto MS, Walls AC, Diamond MS, Telenti A, Virgin HW, Lanzavecchia A, Veesler D, Snell G, Corti D. Cameroni E, et al. bioRxiv [Preprint]. 2021 Dec 20:2021.12.12.472269. doi: 10.1101/2021.12.12.472269. bioRxiv. 2021. Update in: Nature. 2022 Feb;602(7898):664-670. doi: 10.1038/s41586-021-04386-2 PMID: 34931194 Free PMC article. Updated. Preprint.
Dynamics of SARS-CoV-2 VOC neutralization and novel mAb reveal protection against Omicron.
Hao L, Hsiang TY, Dalmat RR, Ireton R, Morton J, Stokes C, Netland J, Hale M, Thouvenel C, Wald A, Franko NM, Huden K, Chu H, Greninger A, Tilles S, Barrett LK, Van Voorhis WC, Munt J, Scobey T, Baric RS, Rawlings D, Pepper M, Drain PK, Gale M. Hao L, et al. medRxiv [Preprint]. 2022 Aug 16:2022.08.12.22278720. doi: 10.1101/2022.08.12.22278720. medRxiv. 2022. Update in: Viruses. 2023 Feb 14;15(2):530. doi: 10.3390/v15020530 PMID: 36032965 Free PMC article. Updated. Preprint.
Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection.
Guenthoer J, Lilly M, Starr TN, Dadonaite B, Lovendahl KN, Croft JT, Stoddard CI, Chohan V, Ding S, Ruiz F, Kopp MS, Finzi AS, Bloom JD, Chu HY, Lee KK, Overbaugh J. Guenthoer J, et al. Among authors: chu hy. bioRxiv [Preprint]. 2023 Mar 29:2022.12.15.520606. doi: 10.1101/2022.12.15.520606. bioRxiv. 2023. Update in: Proc Natl Acad Sci U S A. 2023 Jun 6;120(23):e2220948120. doi: 10.1073/pnas.2220948120 PMID: 36561191 Free PMC article. Updated. Preprint.
Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants.
Addetia A, Piccoli L, Case JB, Park YJ, Beltramello M, Guarino B, Dang H, Pinto D, Scheaffer S, Sprouse K, Bassi J, Silacci-Fregni C, Muoio F, Dini M, Vincenzetti L, Acosta R, Johnson D, Subramanian S, Saliba C, Giurdanella M, Lombardo G, Leoni G, Culap K, McAlister C, Rajesh A, Dellota E, Zhou J, Farhat N, Bohan D, Noack J, Lempp FA, Cameroni E, Whitener B, Giannini O, Ceschi A, Ferrari P, Franzetti-Pellanda A, Biggiogero M, Garzoni C, Zappi S, Bernasconi L, Kim MJ, Schnell G, Czudnochowski N, Franko N, Logue JK, Yoshiyama C, Stewart C, Chu H, Schmid MA, Purcell LA, Snell G, Lanzavecchia A, Diamond M, Corti D, Veesler D. Addetia A, et al. bioRxiv [Preprint]. 2023 Feb 27:2023.01.17.523798. doi: 10.1101/2023.01.17.523798. bioRxiv. 2023. PMID: 36711984 Free PMC article. Preprint.
Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.
Walls AC, Fiala B, Schäfer A, Wrenn S, Pham MN, Murphy M, Tse LV, Shehata L, O'Connor MA, Chen C, Navarro MJ, Miranda MC, Pettie D, Ravichandran R, Kraft JC, Ogohara C, Palser A, Chalk S, Lee EC, Guerriero K, Kepl E, Chow CM, Sydeman C, Hodge EA, Brown B, Fuller JT, Dinnon KH 3rd, Gralinski LE, Leist SR, Gully KL, Lewis TB, Guttman M, Chu HY, Lee KK, Fuller DH, Baric RS, Kellam P, Carter L, Pepper M, Sheahan TP, Veesler D, King NP. Walls AC, et al. Among authors: chu hy. Cell. 2020 Nov 25;183(5):1367-1382.e17. doi: 10.1016/j.cell.2020.10.043. Epub 2020 Oct 31. Cell. 2020. PMID: 33160446 Free PMC article.
Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects.
Jennewein MF, MacCamy AJ, Akins NR, Feng J, Homad LJ, Hurlburt NK, Seydoux E, Wan YH, Stuart AB, Edara VV, Floyd K, Vanderheiden A, Mascola JR, Doria-Rose N, Wang L, Yang ES, Chu HY, Torres JL, Ozorowski G, Ward AB, Whaley RE, Cohen KW, Pancera M, McElrath MJ, Englund JA, Finzi A, Suthar MS, McGuire AT, Stamatatos L. Jennewein MF, et al. Among authors: chu hy. bioRxiv [Preprint]. 2021 Mar 24:2021.03.23.436684. doi: 10.1101/2021.03.23.436684. bioRxiv. 2021. Update in: Cell Rep. 2021 Jul 13;36(2):109353. doi: 10.1016/j.celrep.2021.109353 PMID: 33791692 Free PMC article. Updated. Preprint.
463 results